文献速递神经肿瘤

脑膜瘤的多组学全景:综述与更新

The multiomic landscape of meningiomas: a review and update.
PubMed 文献 · J Neurooncol · 2023-02-25

脑膜瘤是成人最常见的原发性脑肿瘤,近十年多项研究整合基因组与表观基因组平台,提出可超越组织病理学分级、更准确预测肿瘤生物学行为与术后结局的分子分型;综述归纳这些关键改变,并整合为四个共识分子组:两个以NF2状态区分的良性组,以及分别以高代谢转录组和增殖性细胞周期通路为特征的兩個临床侵袭性组。

要点

  • 脑膜瘤分子分型在诊断准确性、生物学相关性和结局预测上可能超越WHO分级。
  • 不同研究命名的分子组可整合为四个共识分子组:两个良性组、两个临床侵袭性组。
  • 良性组主要由NF2状态二分,侵袭性组分别以高代谢转录组和增殖性细胞周期通路为特征。

核心结论

  • 近期研究揭示的分子组在准确预测肿瘤生物学行为和术后临床结局方面超越WHO分级和其他临床因素。
  • 不同研究命名的分子组虽存在差异,但生物学相似性使这些组可能整合为四个共识分子组。

研究设计与样本

  • 综述:总结整合不同基因组和表观基因组平台、发现脑膜瘤关键驱动改变并构建分子分型的研究。

主要发现

  • 四个共识分子组包括两个良性组,主要由NF2状态二分。
  • 两个临床侵袭性组分别以高代谢转录组和以增殖性、细胞周期通路为主为特征。

关键数值与推荐

  • 分子组在准确预测肿瘤生物学和术后临床结局方面超越WHO分级和其他临床因素。

局限性

  • 原文指出未来工作需要验证这些分子组并统一命名以供常规临床使用,包括作者团队在内的多项工作正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meningiomas are the most common primary brain tumor in adults. Traditionally they have been understudied compared to other central nervous system (CNS) tumors. However over the last decade, there has been renewed interest in uncovering the molecular topography of these tumors, with landmark studies identifying key driver alterations contributing to meningioma development and progression. Recent work from several independent research groups have integrated different genomic and epigenomic platforms to develop a molecular-based classification scheme for meningiomas that could supersede histopathological grading in terms of diagnostic accuracy, biological relevance, and outcome prediction, keeping pace with contemporary grading schemes for other CNS tumors including gliomas and medulloblastomas. METHODS: Here we summarize the studies that have uncovered key alterations in meningiomas which builds towards the discovery of consensus molecular groups in meningiomas by integrating these findings. These groups supersede WHO grade and other clinical factors in being able to accurately predict tumor biology and clinical outcomes following surgery. RESULTS: Despite differences in the nomenclature of recently uncovered molecular groups across different studies, the biological similarities between these groups enables us to likely reconciliate these groups into four consensus molecular groups: two benign groups largely dichotomized by NF2-status, and two clinically aggressive groups defined by their hypermetabolic transcriptome, and by their preponderance of proliferative, cell-cycling pathways respectively. CONCLUSION: Future work, including by our group and others are underway to validate these molecular groups and harmonize the nomenclature for routine clinical use.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wang JZ, Nassiri F, Landry AP, et al. The multiomic landscape of meningiomas: a review and update. J Neurooncol. 2023. PMID: 36840836. doi:10.1007/s11060-023-04253-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。